SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 21, 2004
-------------
SANGUI BIOTECH INTERNATIONAL, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado
------------------------------------------------------------
(State or other jurisdiction of Incorporation or organization
000-21271 84-1330732
----------------------------------- -----------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
--------------------------------------------------
(Address of principal executive offices)(Zip Code)
011-49-2302-915-204
---------------------------------------------------
(Registrant's telephone number, including area code)
N/A
------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 9. Regulation FD Disclosure
Sangui BioTech and German Pharmaceutical Company Plan Joint Development of
Haemoglobin Wound Spray
On June 21, 2004 Sangui Biotech International, Inc. (NASD OTCBB: SGBI)
issued a press release announcing that a renowned German medium sized
pharmaceutical company and SanguiBioTech GmbH of Witten, Germany, a wholly owned
subsidiary of Sangui BioTech International, Inc., have declared their intention
to jointly develop a haemoglobin wound spray based on Sangui's artificial oxygen
carrier for the treatment of chronic wounds. The product has undergone a number
of initial clinical experiments which give rise to the expectation that the new
product may revolutionize the treatment of chronic wounds.
Under the proposed agreement, the pharmaceutical company will acquire the
pertinent know-how, rights and patents from Sangui. The partners plan to jointly
prepare and promote international regulatory clearance of the haemoglobin wound
spray as a pharmaceutical, which then will be internationally marketed by the
pharmaceutical company. Sangui will participate in future sales of the product
through royalties. Both companies expect to sign the contract after approval by
the Supervisory Boards in August, 2004. A copy of the press release is furnished
as Exhibit 99.1 to this report.
The information in this Current Report on Form 8-K, including the exhibit,
is furnished under "Item 2. Management's Discussion and Analysis of Financial
Condition" in accordance with SEC Release No. 33-8216. Furthermore, the
information in this Current Report on Form 8-K, including the exhibit, shall not
be deemed to be incorporated by reference into the filings of the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,
as amended.
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.
Sangui Biotech International, Inc.
(Registrant)
Date: June 21, 2004 /s/ Wolfgang Barnikol
----------------------------
By: Wolfgang Barnikol
Its: President, CEO and CFO
3
INDEX TO EXHIBITS
Exhibit Number Exhibit
-------------- ---------
99.1 Press Release dated June 21, 2004*
* This exhibit is furnished to, but not filed with, the Commission by inclusion
herein.